BioCentury
ARTICLE | Management Tracks

Li departs LianBio as CEO; plus Xilio, Myriad, OKYO and Intravacc

March 30, 2021 1:36 AM UTC

Bing Li has left Perceptive Advisors-backed cross-border company LianBio as CEO, according to his LinkedIn page. Li’s previous roles include CEO of China Biologic Products Holdings Inc. (NASDAQ:CBPO), chairman of Ambrx Inc. and managing director and head of overseas healthcare private equity investment at Shanghai Fosun Pharmaceutical Group Co. Ltd. (Shanghai:600196; HKEX:2196). LianBio has made no formal announcement; however, Li no longer appears on the company’s website.

Cancer immunotherapy company  Xilio Therapeutics Inc. hired Salvatore Giovine as CFO and Chris Frankenfield as general counsel. Giovine is a 15-year veteran of Johnson & Johnson (NYSE:JNJ), where he most recently led finance for the U.S. oncology business of Janssen Biotech Inc. Frankenfield was VP of corporate legal affairs at Blueprint Medicines Corp. (NASDAQ:BPMC)...